Oncology Total Other Income Expense Net from 2010 to 2024

TOIIW Stock  USD 0.02  0  26.85%   
Oncology Institute Total Other Income Expense Net yearly trend continues to be fairly stable with very little volatility. Total Other Income Expense Net is likely to outpace its year average in 2024. During the period from 2010 to 2024, Oncology Institute Total Other Income Expense Net regression line of quarterly data had mean square error of 510 T and geometric mean of  342,200. View All Fundamentals
 
Total Other Income Expense Net  
First Reported
2018-12-31
Previous Quarter
885 K
Current Value
-2.3 M
Quarterly Volatility
11.8 M
 
Covid
Check Oncology Institute financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncology Institute's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.8 M, Interest Expense of 7.1 M or Selling General Administrative of 67.6 M, as well as many indicators such as Price To Sales Ratio of 0.44, Dividend Yield of 0.0235 or PTB Ratio of 2.51. Oncology financial statements analysis is a perfect complement when working with Oncology Institute Valuation or Volatility modules.
  
Check out the analysis of Oncology Institute Correlation against competitors.
For more information on how to buy Oncology Stock please use our How to Invest in Oncology Institute guide.

Latest Oncology Institute's Total Other Income Expense Net Growth Pattern

Below is the plot of the Total Other Income Expense Net of The Oncology Institute over the last few years. It is Oncology Institute's Total Other Income Expense Net historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Oncology Institute's overall financial position and show how it may be relating to other accounts over time.
Total Other Income Expense Net10 Years Trend
Slightly volatile
   Total Other Income Expense Net   
       Timeline  

Oncology Total Other Income Expense Net Regression Statistics

Arithmetic Mean6,551,433
Geometric Mean342,200
Coefficient Of Variation349.63
Mean Deviation13,735,618
Median71,175
Standard Deviation22,905,550
Sample Variance524.7T
Range88.5M
R-Value0.31
Mean Square Error510T
R-Squared0.1
Significance0.26
Slope1,598,463
Total Sum of Squares7345.3T

Oncology Total Other Income Expense Net History

2024-5.8 M
2023-6.1 M
202281.9 M
202134.3 M
2020-6.6 M
2019 -3375.0

About Oncology Institute Financial Statements

Oncology Institute investors use historical fundamental indicators, such as Oncology Institute's Total Other Income Expense Net, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Oncology Institute. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Other Income Expense Net-6.1 M-5.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Oncology Stock Analysis

When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.